Genome-Wide Association Study of Circulating Estradiol, Testosterone, and Sex Hormone-Binding Globulin in Postmenopausal Women

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS ONE (Impact Factor: 3.23). 06/2012; 7(6):e37815. DOI: 10.1371/journal.pone.0037815
Source: PubMed


Genome-wide association studies (GWAS) have successfully identified common genetic variants that contribute to breast cancer risk. Discovering additional variants has become difficult, as power to detect variants of weaker effect with present sample sizes is limited. An alternative approach is to look for variants associated with quantitative traits that in turn affect disease risk. As exposure to high circulating estradiol and testosterone, and low sex hormone-binding globulin (SHBG) levels is implicated in breast cancer etiology, we conducted GWAS analyses of plasma estradiol, testosterone, and SHBG to identify new susceptibility alleles. Cancer Genetic Markers of Susceptibility (CGEMS) data from the Nurses' Health Study (NHS), and Sisters in Breast Cancer Screening data were used to carry out primary meta-analyses among ~1600 postmenopausal women who were not taking postmenopausal hormones at blood draw. We observed a genome-wide significant association between SHBG levels and rs727428 (joint β = -0.126; joint P = 2.09 × 10(-16)), downstream of the SHBG gene. No genome-wide significant associations were observed with estradiol or testosterone levels. Among variants that were suggestively associated with estradiol (P<10(-5)), several were located at the CYP19A1 gene locus. Overall results were similar in secondary meta-analyses that included ~900 NHS current postmenopausal hormone users. No variant associated with estradiol, testosterone, or SHBG at P<10(-5) was associated with postmenopausal breast cancer risk among CGEMS participants. Our results suggest that the small magnitude of difference in hormone levels associated with common genetic variants is likely insufficient to detectably contribute to breast cancer risk.

Download full-text


Available from: Immaculata De Vivo
  • Source
    • "After the cessation of ovarian estrogen production at menopause, endogenous estrogens are primarily synthesized from testosterone (T) in adipose tissue via aromatase, encoded by CYP19A1. Candidate gene studies have found levels of E 2 in pre-menopausal and postmenopausal women, and also in men, to be associated with genetic variants within or close to CYP19A1 (Dunning et al. 2004, Paynter et al. 2005, Haiman et al. 2007, Ahn et al. 2009, Eriksson et al. 2009, Kidokoro et al. 2009, Travis et al. 2009, Beckmann et al. 2011, Lundin et al. 2012, Prescott et al. 2012, Flote et al. 2014). Candidate studies have also identified associations between several different CYP19A1 variants and endometrial cancer (Paynter et al. 2005, Tao et al. 2007, Setiawan et al. 2009, Low et al. 2010), with some evidence of stronger associations in women with higher BMI (Setiawan et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Candidate gene studies have reported CYP19A1 variants to be associated with endometrial cancer and with estradiol concentrations. We analysed 2,937 SNPs in 6,608 endometrial cancer cases and 37,925 controls and report the first genome wide-significant association between endometrial cancer and a CYP19A1 SNP (rs727479 in intron 2, P=4.8x10-11). SNP rs727479 was also among those most strongly associated with circulating estradiol concentrations in 2,767 post-menopausal controls (P=7.4x10-8). The observed endometrial cancer odds ratio per rs727479 A-allele (1.15, CI=1.11-1.21) is compatible with that predicted by the observed effect on estradiol concentrations (1.09, CI=1.03-1.21), consistent with the hypothesis that endometrial cancer risk is driven by estradiol. From 28 candidate-causal SNPs, 12 co-located with three putative gene-regulatory elements and their risk alleles associated with higher CYP19A1 expression in bioinformatical analyses. For both phenotypes, the associations with rs727479 were stronger among women with a higher BMI (Pinteraction=0.034 and 0.066 respectively), suggesting a biologically plausible gene-environment interaction.
    Full-text · Article · Nov 2015 · Endocrine Related Cancer
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Mammographic breast density and endogenous sex-hormone levels are both strong risk factors for breast cancer. This study investigated whether there is evidence for a shared genetic basis between these risk factors. METHODS: Using data on 1286 women from 617 families we estimated the heritabilities of serum estradiol, testosterone and sex-hormone binding globulin (SHBG) levels and of three measures of breast density (dense area, non-dense area and percent density). We tested for associations between hormone levels and density measures, and estimated the genetic and environmental correlations between pairs of traits using variance and co-variance components models and pedigree-based maximum likelihood methods. RESULTS: We found no significant associations between estradiol, testosterone or SHBG levels and any of the three density measures, after adjusting for BMI. The estimated heritabilities were 63%, 66% and 65% for square-root transformed adjusted percent-density, dense area and non-dense area respectively, and 40%, 25% and 58% for log-transformed adjusted estradiol, testosterone and SHBG. We found no evidence of a shared genetic basis between any hormone levels and any measure of density, after adjusting for BMI. The negative genetic correlation between dense and non-dense areas remained significant even after adjustment for BMI and other covariates (p=-0.34, se=0.08, P=0.0005). Conclusions and Impact: Breast density and sex hormones can thus be considered as independent sets of traits, each of which can be used as intermediate phenotypes in the search for breast cancer susceptibility loci.
    Full-text · Article · Oct 2012 · Cancer Epidemiology Biomarkers & Prevention
  • [Show abstract] [Hide abstract]
    ABSTRACT: Even though the levels of circulating sex steroid hormones are to a large extent heritable, their genetic determinants are largely unknown. With the advent of genome-wide association studies (GWAS), much progress has been made and several genetic loci have been identified to be associated with serum levels of dehydroepiandrosterone sulfate, testosterone and sex hormone-binding globulin. The variants identified so far only explain a small amount of the overall heritability, but may help to elucidate the role of sex steroid hormones in common disorders such as hypogonadism, type 2 diabetes and hormone-sensitive cancers. This review provides an overview of the current state of knowledge of the genetic determinants of sex steroid hormones, with a focus on recent GWAS and brief directions for elucidating the remaining heritability.
    No preview · Article · Mar 2013 · Molecular and Cellular Endocrinology
Show more